BioSpace News Archive

Ginkgo is building the leading horizontal platform for synthetic biology, making it possible to program cells as easily as we can program computers and enabling innovation across industries, including therapeutics, industrials, food and agriculture

Castle Biosciences, Inc., a skin cancer diagnostics company providing personalized genomic information to improve cancer treatment decisions, announced that Tiffany Olson has been appointed to its board of directors, effective immediately.

Enanta Pharmaceuticals, Inc., a clinical stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, announced that Jay R. Luly, Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the RBC Capital Markets Global Healthcare Conference on May 18, 2021 at 1:20 p.m. ET.

Zoetis Inc. (NYSE:ZTS) today announced leadership changes that will accelerate its long-term growth strategy in key markets and add new talent to its executive team. Glenn David, Executive Vice President and Chief Financial Officer (CFO) for Zoetis, has been named Executive Vice President and Group President, overseeing International Operations and other business units, effective June 1, 2021.

AngioSoma, Inc. (OTC PINK:SOAN) has added Darryl Morris as a Strategic Economic Advisor. Morris has over three decades of economic, strategic, and market intelligence experience working with companies, such as Abbott Laboratories.

- Enrollment Now Underway in Multiple Solid Tumor and Hematologic Malignancy Expansion Cohorts in Phase 1 Trial of Oral PRMT5 Inhibitor PRT543 - - Initial Clinical Data Readouts for Lead Oral PRMT5 Inhibitors PRT543 and PRT811 Expected in 2H21 - - Dose Escalation Ongoing in Phase 1 Trial of Oral MCL1 Inhibitor PRT1419, with Dose Expansion Cohorts on Track to be Added in 2H21 -

- Next data readout for ASLAN004 in the treatment of patients with moderate to severe atopic dermatitis anticipated in the third quarter of 2021 - Phase 2b clinical trial for ASLAN004 expected to initiate in the second half of 2021

CSL Behring Canada announced that HAEGARDA®, is now available in all of Canada.

The National Headache Foundation announced findings from a new survey, Preventing Migraine Attacks: A Current Perspective, which characterizes the experiences of people living with migraine and highlights the physical and emotional barriers to preventive treatment.

Transparency Market Research has published a new report titled, ‘Sample Preparation Market - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2019–2027’.